Point72 Asia (Singapore) Pte. Ltd. Arcutis Biotherapeutics, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $379 Billion
- Q4 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 1,626 shares of ARQT stock, worth $25,576. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,626Holding current value
$25,576% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding ARQT
# of Institutions
219Shares Held
129MCall Options Held
2.02MPut Options Held
202K-
Jennison Associates LLC12.3MShares$194 Million0.11% of portfolio
-
Suvretta Capital Management, LLC New York, NY11.4MShares$179 Million6.61% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$173 Million2.52% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$138 Million7.34% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$136 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $947M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...